The hereditary hemorrhagic telangiectasia (HHT) treatment landscape continues to grow.

On September 29, Tectonic Therapeutic announced early clinical results for TX2100, an investigational therapy being developed for hereditary hemorrhagic telangiectasia (HHT). The company also announced that the US Food and Drug Administration (FDA) has granted TX2100 Fast Track designation and cleared its Investigational New Drug application, allowing Tectonic to move forward with a planned clinical trial in people with HHT in the US.

The initial Phase 1 study was conducted in healthy volunteers, so important questions about TX2100’s safety and potential effectiveness in people with HHT remain to be studied. Still, the advancement of another potential therapy into HHT clinical research is an encouraging sign of the continued growth and diversification of the HHT treatment pipeline.

“For people living with HHT, every credible new approach entering patient studies matters—not because early data guarantee an answer, but because a stronger and more diverse pipeline gives our community more opportunities to find one,” said Marianne Clancy, MPA, Chief Executive Officer of Cure HHT. “We are encouraged to see TX2100 moving into the next stage of research. The important work now is learning what this approach can do in people living with HHT, and we look forward to seeing the science continue to develop.”

Cure HHT will continue following the development of TX2100 and other investigational therapies across the HHT research landscape and sharing meaningful updates with our community as evidence emerges.

Read Tectonic Therapeutic’s full announcement:
https://investors.tectonictx.com/news-releases/news-release-details/tectonic-therapeutic-announces-favorable-phase-1-safety

Please note: At this time, Tectonic Therapeutic is not a partner in the Cure HHT Clinical Trial Network. Cure HHT shares information about HHT research and clinical trials to help our community stay informed about developments across the field.